s-1-(combination) and Corneal-Diseases

To identify predictive factors for ocular complications caused by the anticancer drug S-1.. A questionnaire was administered to 39 patients who underwent S-1 chemotherapy at Kobe City Medical Center General Hospital, with the aim to determine whether these patients were aware of the ocular complications caused by S-1. Cognition rate was determined. The 26 patients who requested opthalmological examination for further evaluation studied further and classified into two groups-those who had developed corneal epithelial complications, conjunctival injection or chemosis, or lacrimal duct blockages (referred to as the positive group) and those without these findings (referred to as the negative group). Predictive factors, such as age, sex, total administration days, total dose, presence or absence of anticancer drug pretreatment, and single-drug or combination-drug therapy, were investigated and compared between groups.. Of the 39 patients who completed the questionnaire, ten were aware of the potential for ocular complications due to S-1 chemotherapy (cognition rate 25.6 %). Of the 26 patients who had requested opthalmological examination and entered into the study, 13 (26 eyes) were classified into the positive group, with corneal complications observed in 15 eyes (57.7 %), conjunctivitis in 26 eyes (100 %), and lacrimal duct blockage in 14 eyes (53.8 %). Cognition rate in the 13 patients in the positive group and the 13 patients in the negative group was 38.5 % (5 patients) and 7.7 % (1 patient), respectively. Patient age was significantly different between the two groups, with the patients in the positive group being significantly older than those in the negative group (mean age ± standard deviation: 71.6 ± 6.8 vs. 63.5 ± 7.3 years, respectively; P = 0.0077, Student's t test). No other significant predictive factors were detected.. Older patients were at greater risk of S-1-related ocular complications, but these complications were not associated with total administration days or total dose.

Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; Drug Combinations; Female; Health Knowledge, Attitudes, Practice; Humans; Japan; Lacrimal Duct Obstruction; Male; Middle Aged; Neoplasms; Oxonic Acid; Risk Factors; Surveys and Questionnaires; Tegafur

An oral antineoplastic drug, S-1, is known to be more effective with less toxicity and fewer gastrointestinal side effects than the conventional intravenous 5-fluorouracil. We report a case of limbal stem cell deficiency that occurred in a patient receiving chemotherapy using S-1 alone for gastric cancer.. A 65-year-old woman with symptoms of grittiness and epiphora in both eyes for several months was referred to the ophthalmology clinic. She had been receiving S-1 orally after total gastrectomy for advanced gastric cancer. Slit lamp examination revealed an irregular hazy corneal epithelium in both eyes that extended to the center of the cornea overlying the pupil and showed late staining with fluorescein dye. Palisades of Vogt at the superior limbus were absent in both eyes. Best-corrected distance vision was 20/50 in both eyes with all other structures of the anterior and posterior segment unremarkable including a patent lacrimal drainage system. There was no change in the corneal lesions of either eye despite 3 months of topical therapy. The lesions did resolve in 4 months after discontinuation of S-1 therapy owing to acute renal failure.. Early detection of this adverse reaction before significant visual loss through regular follow-up appears to be important in patients receiving S-1 therapy.

Topics: Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Epithelium, Corneal; Female; Gastrectomy; Humans; Limbus Corneae; Oxonic Acid; Stem Cells; Stomach Neoplasms; Tegafur; Visual Acuity

Topics: Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; Drug Combinations; Epithelial Cells; Humans; Lacrimal Duct Obstruction; Neoplasms; Oxonic Acid; Tegafur

Topics: Aged; Antimetabolites, Antineoplastic; Conjunctival Diseases; Corneal Diseases; Drug Combinations; Epithelium, Corneal; Humans; Lung Neoplasms; Male; Oxonic Acid; Pigmentation Disorders; Tegafur

Topics: Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Dry Eye Syndromes; Eyelid Diseases; Female; Humans; Male; Meibomian Glands; Microscopy, Confocal; Middle Aged; Neoplasms; Oxonic Acid; Tegafur

S-1 is a new oral anticancer drug containing tegafur, which is a prodrug of 5-fluorouracil. In this report, we describe the clinical features of three patients who suffered corneal disorders that seemed to be caused by S-1 administration.. One female and two male patients, whose ages ranged from 57 to 69 years, were entered in this study. Between 3 to 14 months after they started oral S-1 therapy, they experienced sudden visual reduction. They all had corneal disorders, which occurred in the inferior and the superior areas, and progressed toward the center. As the corneal disorders invaded the pupil area, the patients noticed visual disturbance. They recovered their vision and their corneal disorders diminished when the drug was discontinued. However, after the drug intake was resumed, the corneal disorders occurred again in some cases. All patients also had lacrimal obstructions.. S-1 treated patients should be followed carefully for ophthalmic complications because corneal disorders are likely to appear.

Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Female; Humans; Lacrimal Duct Obstruction; Male; Middle Aged; Oxonic Acid; Prodrugs; Tegafur